Article
A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy.
Leukemia - 1 Mar 2007
Stewart A K, Bergsagel P L, Greipp P R, Dispenzieri A, Gertz M A, Hayman S R, Kumar S, Lacy M Q, Lust J A, Russell S J, Witzig T E, Zeldenrust S R, Dingli D, Reeder C B, Roy V, Kyle R A, Rajkumar S V, Fonseca R
Abstract excerpt
Clinical outcomes for multiple myeloma (MM) are highly heterogeneous and it is now clear that pivotal genetic events are the primary harbingers of such variation. These findings have broad implications for counseling, choice of therapy and the design and interpretation of clinical investigation. Indeed, as in acute leukemias and non-hodgkins lymphoma, we believe it is no longer acceptable to consider MM a single...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.